ARA-290 vs Normoftal
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Cibinetide, ARA 290
ARA-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (EPO), engineered to calm inflammation and repair nerves without thickening the blood the way EPO does. It has been tested in real Phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug status, but it was never approved and development largely stalled. So: genuine clinical data, promising signals, no finish line.
Also: Eye Peptide Bioregulator, Retina Peptide
Normoftal is an obscure Russian eye supplement from the Khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. Be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. We keep the claims minimal on purpose.
Key Comparison Insights
- Both peptides belong to the Cognitive category, suggesting similar primary applications.
Detailed Comparison
| Attribute | ARA-290 | Normoftal |
|---|---|---|
| Category | Cognitive | Cognitive |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | EPO does two jobs - it tells bone marrow to make red blood cells, and separately it protects and repairs injured tissue. ARA-290 was designed to trigger only the second job. It selectively activates the innate repair receptor (IRR), a heteroreceptor that pairs the EPO receptor with the CD131 beta-common chain and shows up at sites of injury and inflammation. By switching on this receptor, the peptide dampens inflammatory signaling and reduces cell death while leaving red blood cell production alone, which sidesteps EPO's clotting and cardiovascular risks. Some research also links its pain-relieving effect to modulation of the TRPV1 channel where the immune system and nociception intersect. | Khavinson's bioregulator theory holds that very short peptides (two to four amino acids) extracted from or modeled on a specific tissue can act as tissue-specific signals, switching gene expression and protein synthesis back toward normal in that organ. Normoftal is the eye/retina version, described as containing a synthesized peptide (marketed as 'AKS-G,' reportedly lysine and glutamic acid) intended to support retinal cells. The proposed mechanism is that the peptide corrects an age- or disease-related 'peptide deficiency' and restores normal cellular function in the retina. This is a hypothesis from one school of research, not a mechanism confirmed by independent molecular studies, and the specific composition claims come from vendors rather than peer-reviewed identification. |
| Common Dosing | 4 mg daily Once daily | 2 capsules 1-2x daily 1-2x daily, before meals |
| Administration | Subcutaneous injection | Oral capsules, before meals |
| Typical Duration | 28-day courses in trials | 30-day courses, repeat after 2-6 months |
| Best Time to Take | Consistent daily timing | Morning and evening, before meals |
Possible Side Effects May vary by individual |
|
|
| Research Summary | ARA-290 has more real human data than most peptides in this category. A 2015 phase 2 trial published in Molecular Medicine (Brines et al., registered as NTR3858) found that ARA-290 improved hemoglobin A1c and lipid profile and significantly improved PainDetect neuropathic symptom scores in type 2 diabetes patients, with increased corneal nerve fiber density in those with small fiber neuropathy. In sarcoidosis-associated small fiber neuropathy, controlled studies reported increased corneal nerve fiber area and more regenerating (GAP-43-positive) skin nerve fibers, though in at least one dose-ranging trial pain did not clearly separate from placebo - an honest caveat worth keeping. Tolerability in these small, early-phase studies has been favorable, with no signal of EPO-style blood thickening. That said, the trials are small and early, ARA-290 holds FDA orphan drug status for sarcoidosis neuropathy but is not approved, and the program stalled around 2020. Net: real clinical evidence pointing in a hopeful direction, but not yet proven enough to be a standard treatment. | Normoftal is sold in Russia as a dietary supplement and is marketed for retinal degeneration, glaucoma, cataracts, diabetic retinopathy, and post-surgical recovery. Here is the part that matters most: it is not FDA-approved, and the evidence for Khavinson-style retinal bioregulators is heavily concentrated within Khavinson's own institute and clinical program, not replicated by independent international groups to modern standards. The related pharmaceutical Retinalamin is registered for clinical use in Russia, but that registration reflects the Russian system, not FDA or EMA review. There are essentially no rigorous, independent, placebo-controlled trials specific to Normoftal itself in mainstream literature. Treat the marketed eye-health benefits as unproven claims, and treat confidence in this compound as low. |
Frequently Asked Questions: ARA-290 vs Normoftal
What is the difference between ARA-290 and Normoftal?
ARA-290 is a cognitive peptide that ara-290 (cibinetide) is a synthetic 11-amino-acid peptide carved from the tissue-protective region of erythropoietin (epo), engineered to calm inflammation and repair nerves without thickening the blood the way epo does. it has been tested in real phase 2 human trials, mainly for sarcoidosis-related small fiber neuropathy and diabetic neuropathy, and holds fda orphan drug status, but it was never approved and development largely stalled. so: genuine clinical data, promising signals, no finish line. Normoftal is a cognitive peptide that normoftal is an obscure russian eye supplement from the khavinson 'peptide bioregulator' tradition, sold as short peptides meant to support the retina. be clear-eyed about this one: it is marketed as a dietary supplement, not an approved drug, and the evidence behind it is thin and comes almost entirely from one research lineage. we keep the claims minimal on purpose. The main differences lie in their mechanisms of action and clinical applications.
Which is better, ARA-290 or Normoftal?
Neither is universally "better" - the choice depends on your specific goals. ARA-290 is typically used for cognitive purposes, while Normoftal is used for cognitive. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can ARA-290 and Normoftal be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using ARA-290 and Normoftal together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.